Pay in 4 interest-free payments of $5.54 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
Its FDA label has grown from a single T2D indication in 2017 to six approved indications by early 2026: type 2 diabetes, chronic weight management (injectable and oral), cardiovascular risk reduction, chronic kidney disease protection, and MASH
The synthetic analog achieves therapeutic concentrations that exceed those of endogenous GLP-1, resulting in more robust appetite suppression and metabolic improvement
Below 72 hours
This damage does not reverse upon thawing
Investor concern is that the company is losing market share to its US rival Eli Lilly, which makes the diabetes and obesity drugs Mounjaro and Zepbound
[1] [4] Understanding GLP-1 physiology has become increasingly relevant with the development of GLP-1 receptor agonists (such as semaglutide and liraglutide) for diabetes and, under specific criteria, weight management
US$ 29.54
US$ 22.93
US$ 24.01
US$ 25.80
US$ 20.69
US$ 26.21
US$ 23.27
US$ 24.07
US$ 25.61
US$ 28.67
